- Home
- TTRX vs AARD Comparison
TTRX vs AARD Comparison
Compare TTRX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTRX
- AARD
- Stock Information
- Founded
- TTRX 2015
- AARD 2017
- Country
- TTRX United States
- AARD United States
- Employees
- TTRX N/A
- AARD N/A
- Industry
- TTRX Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TTRX Health Care
- AARD Health Care
- Exchange
- TTRX Nasdaq
- AARD Nasdaq
- Market Cap
- TTRX 257.8M
- AARD 231.9M
- IPO Year
- TTRX N/A
- AARD 2025
- Fundamental
- Price
- TTRX $4.15
- AARD $10.72
- Analyst Decision
- TTRX
- AARD Strong Buy
- Analyst Count
- TTRX 0
- AARD 8
- Target Price
- TTRX N/A
- AARD $30.75
- AVG Volume (30 Days)
- TTRX 133.1K
- AARD 169.3K
- Earning Date
- TTRX 01-01-0001
- AARD 11-13-2025
- Dividend Yield
- TTRX N/A
- AARD N/A
- EPS Growth
- TTRX N/A
- AARD N/A
- EPS
- TTRX N/A
- AARD N/A
- Revenue
- TTRX N/A
- AARD N/A
- Revenue This Year
- TTRX N/A
- AARD N/A
- Revenue Next Year
- TTRX N/A
- AARD N/A
- P/E Ratio
- TTRX N/A
- AARD N/A
- Revenue Growth
- TTRX N/A
- AARD N/A
- 52 Week Low
- TTRX $3.65
- AARD $4.88
- 52 Week High
- TTRX $26.50
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TTRX N/A
- AARD 43.96
- Support Level
- TTRX N/A
- AARD $9.34
- Resistance Level
- TTRX N/A
- AARD $10.94
- Average True Range (ATR)
- TTRX 0.00
- AARD 0.84
- MACD
- TTRX 0.00
- AARD -0.03
- Stochastic Oscillator
- TTRX 0.00
- AARD 47.87
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.